October Upside Ranks
Qualitative relative target-touch selections · Not calibrated probabilities
Dated prices · targets are price touches, not forecasts · exact ranks are editorial judgments.
Grade legend, dates & research limits
Completed editorial grades · assessed October 6. Business = demonstrated commercial traction. Catalyst = clarity and timing of the next important test, not success odds. Target path = how demanding this list’s target is. These grades use the same rubric for all selected names; they are not native financial-model grades or statistical probabilities.
A strong / direct · B supported but conditional · C speculative or major gaps · D exceptional leap / weak bridge. A strong catalyst can fail. A fivefold target can have a D path even in a top-ranked moonshot.
Exact grading benchmarks & evidence dates
Business
How far the business inflection is demonstrated today, not source completeness.
- A — Broad, realized commercial growth or earnings; not just a plan.
- B — Real but early, concentrated or mixed operating traction.
- C — Primarily clinical/development or capacity optionality; limited realized economics.
- D — Retained facts undermine the proposed business inflection.
Catalyst
Specificity, observability and timing of a thesis-changing test inside the original window, not its chance of success.
- A — A scheduled or explicitly windowed material readout, launch or commercial ramp; repeated hard operating tests may qualify.
- B — Concrete delivery, orders or earnings tests, but diffuse timing or less discrete thesis change.
- C — A real milestone with important acceptance/economics/timing gaps.
- D — No supported material in-window test.
Target path
Burden of reaching THIS tier target from the dated baseline; not an absolute odds estimate.
- A — Comparatively direct earnings/recognition bridge in retained evidence; still conditional.
- B — Recognizable bridge, but meaningful premium, execution or share-claim sensitivity.
- C — Speculative extension or binary rerating beyond established economics; small-base elasticity is not a forecast.
- D — Exceptional leap far beyond retained cases, with major scale/valuation/financing obstacles.
No bell curve, numeric weights, A+ grades, probability conversion or grade-based reranking. Same rubric for incumbents and additions; target-path grades vary by tier. A catalyst can fail. No synchronized chart grading because technical coverage is not comparable across all 19.
Assessment October 6 of retained evidence, not an October 6 source refresh. Baseline October 1; existing remaining touch window October 4, 2026 to exclusive October 1, 2027. Original source cutoff October 3; additions retrieved October 4; Bloom narrative retrieved October 5 UTC. Original publication dates remain attached to sources.
Original conservative research grades remain in each full story. Partial financial underwriting remains partial: completed qualitative grades do not certify current cash, target dilution, clinical efficacy or funded forecasts. No chart grade is invented from unmatched technical snapshots.
Targets use October 1, 2026 baseline quotes, which are not live prices. The price-touch window is October 4, 2026 to exclusive October 1, 2027, not the price at expiry. Exact ordinal differences are low-confidence editorial judgments; absolute likelihood may be low.
Original financial source cutoff: October 3, 2026, 07:14:12.687379 UTC. Biotech sources retrieved October 4 with original publication dates retained. Bloom’s power and policy narrative reviewed October 4 ET (sources retrieved October 5 UTC). Publication does not clear research or model limitations. No calibrated odds.
11
NVDA · SMCI · TSM · NTAP · BE · CRDO · TER · MU · DELL · TWST · SDGR
Explore this list →10
CRDO · SMCI · AXTI · AEHR · COHR · BE · MU · INFQ · ABSI · RXRX
Explore this list →9
AXTI · INFQ · AEHR · CRDO · SMCI · AAOI · NBIS · COHR · ABSI
Explore this list →How to read this edition
Current methodology
The prior addendum overvalued predictable paid earnings as the tie-breaker for a TOUCH-price event. Retain owner economics as a feasibility/downside check, but give genuine measured chart leadership and concrete in-window repricing catalysts greater qualitative importance. No invented numeric weights, new catalyst scores, calibrated hit odds or efficacy forecasts.
Feasibility
Burn, financing and dilution matter, but do not mechanically ban a clinical repricing candidate. June cash is not actual Oct4 cash; funding already in cash/shares is never added twice. Static target equity is not target-specific fully diluted valuation or funded forward fair value.
Original archive: 40 companies / 42 financial routes / 120 dispositions. BE is now selected by editorial thesis, while its financial evidence remains a separate partial comparison (41 names / 123 interpretation decisions). The October 4 addendum reviews 11 additional companies / 33 comparisons, giving 52 comparison names — not 52 fully underwritten models. Only current editorial lists determine membership.
CRWV is not selected in any October tier, by editorial exclusion. No bottom replacement.